Most people live between 4 and 8 years after an Alzheimer’s diagnosis, though the full range stretches from 3 years to more than 20. That wide gap exists because survival depends heavily on age at diagnosis, overall health, sex, and even genetics. Understanding what drives these differences can help you get a clearer picture for your own situation or a loved one’s.
Average Survival After Diagnosis
The most commonly cited range is 4 to 8 years after diagnosis for people aged 65 and older, based on the Alzheimer’s Association’s 2025 report. The Mayo Clinic places the window slightly wider, at 3 to 11 years. Both sources note that some people live 20 years or more, though that’s uncommon.
These numbers can feel vague, and that’s partly because “diagnosis” doesn’t happen at the same point in the disease for everyone. Some people are caught early, others not until moderate symptoms are already present. A person diagnosed in the mild stage has more total time ahead than someone first identified when the disease is already well advanced.
How Each Stage Lasts
Alzheimer’s progresses through roughly four phases: a preclinical stage with no noticeable symptoms, a prodromal stage with mild memory issues that don’t yet qualify as dementia, mild dementia, and moderate to severe dementia. A large modeling study tracked how long each phase lasts depending on the age brain changes begin.
For someone whose disease starts around age 70, the total course is about 20 years. That breaks down to roughly 10 years of silent brain changes before any symptoms appear, 4 years of subtle cognitive slips, 3 years of mild dementia, and 3 years of moderate dementia. Most people aren’t diagnosed until the prodromal or mild dementia stage, which is why post-diagnosis survival is so much shorter than total disease duration.
Age compresses every stage. If the disease begins at 80, the mild dementia phase averages about 2 years and the moderate phase less than 2. If it begins at 60, both stages stretch closer to 3.5 years each. This pattern explains one of the strongest predictors of survival: how old you are when symptoms start.
Age at Diagnosis Makes the Biggest Difference
People diagnosed before age 65, known as early-onset Alzheimer’s, tend to survive longer from the point of diagnosis than those diagnosed later. In one study of over 1,000 patients, people with early-onset disease survived an average of 8 years from their initial assessment, compared to 6.2 years for those diagnosed at 65 or older. That doesn’t mean early-onset patients live to an older age. They die younger in absolute terms (average age 71 versus 84), but the disease itself moves more slowly year by year.
Being older at diagnosis roughly doubles the risk of death. In a large matched cohort study, people with Alzheimer’s who were above the median age at diagnosis had 2.1 times the mortality risk of those below it, even after accounting for sex and socioeconomic factors.
How Sex Affects Survival
Women generally survive longer than men after a dementia diagnosis, which tracks with women’s longer life expectancy overall. Men with Alzheimer’s face about a 58% higher risk of death compared to women. However, the picture is more complicated than “women do better.” Relative to healthy women of the same age, women with dementia actually lose more years of life than men do relative to healthy men.
At age 60, a dementia diagnosis costs women roughly 17 years of expected life, while men lose about 13.5 years. That gap narrows with age but never fully closes. By 85, women still lose about half a year more than men. So while women live longer in absolute terms after diagnosis, the disease steals proportionally more of their remaining lifespan.
Other Health Conditions That Shorten Survival
Existing health problems at the time of diagnosis meaningfully reduce how long someone lives with Alzheimer’s. The conditions with the strongest impact, based on a large matched cohort study, are hip fractures, stroke, and recent cancer treatment, each of which shortened median survival by about 7 to 9 months. Diabetes cut survival by roughly 5.5 months, cardiovascular disease by about 5.5 months, and chronic lung disease by close to 5 months.
These effects were actually more pronounced in younger patients. Someone diagnosed with Alzheimer’s at 60 who also has a history of hip fracture faces a larger relative increase in mortality risk than an 80-year-old with the same combination. The likely reason is that at younger ages, Alzheimer’s alone isn’t expected to cause death quickly, so additional health burdens have more room to change the trajectory.
The Role of Genetics
A gene variant called APOE-e4, which is the strongest known genetic risk factor for Alzheimer’s, also influences how fast cognition declines once the disease is underway. People who carry two copies of this variant (one from each parent) experience cognitive decline roughly twice as fast as those who carry none. In one study, cognitive scores in people with two copies dropped nearly 12 points per year at moderate impairment levels, compared to about 6 points per year in people carrying a protective variant called APOE-e2.
Faster cognitive decline generally means a shorter time spent in the milder stages, which compresses the overall survival window. You won’t necessarily know your APOE status unless you’ve had genetic testing, but this partly explains why two people diagnosed at the same age and stage can have very different trajectories.
What Actually Causes Death
Alzheimer’s itself doesn’t kill in the way a heart attack does. In the earlier stages, people with Alzheimer’s most often die from the same things that kill other older adults: heart disease, stroke, and cancer. Cognitive impairment may make it harder for them to notice or report symptoms of these conditions, which can delay treatment.
In the severe stage, pneumonia becomes the leading cause of death. As the brain loses the ability to coordinate swallowing, food or liquid can enter the lungs, leading to infection. Immobility in the final stage also raises the risk of blood clots and skin infections. On U.S. death certificates in 2022, Alzheimer’s was listed as the cause of death in over 120,000 cases, a rate of 36 deaths per 100,000 people.
Whether New Treatments Change the Timeline
A new class of medications that clear amyloid protein from the brain has begun to shift the conversation. Modeling studies estimate that one of these treatments, lecanemab, could extend overall life expectancy by roughly 1.3 to 1.4 years by delaying progression to more severe stages. The model projects a delay of nearly 2 years before reaching the moderate stage and about 2 years before reaching the severe stage.
These are modeled estimates, not yet confirmed by decades of real-world data, and the treatments are currently approved only for people in early stages of the disease. They also carry risks, including brain swelling and small brain bleeds. Still, they represent the first medications that appear to alter the fundamental timeline of the disease rather than just managing symptoms.
What This Means in Practical Terms
If you’re trying to estimate how much time you or a family member may have, the most useful starting points are age at diagnosis and current stage. A person diagnosed in their early 60s with mild symptoms and no major health problems may have 8 or more years. Someone diagnosed in their 80s with existing heart disease or diabetes is more likely looking at 3 to 5 years. These are averages, not ceilings. Individual variation is enormous, and outliers in both directions are common.
The factors most within your control are managing other health conditions aggressively, staying physically active as long as possible, and maintaining social engagement, all of which are associated with slower functional decline even if they don’t change the underlying brain pathology. The trajectory of Alzheimer’s is not a single fixed path. It’s shaped by biology, health, and care at every stage.